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Abstract
Background—Patients with acute HIV-1 infection (AHI) have elevated infectivity, but cannot 
be diagnosed using antibody-based testing. Approaches to screen patients for AHI are urgently 
needed to enable counselling and treatment to reduce onward transmission.
Methods—We pooled data from four African studies of high-risk adults that evaluated 
symptoms and signs compatible with acute retroviral syndrome and tested for HIV-1 at each visit. 
AHI was defined as detectable plasma viral load or p24 antigen in an HIV-1-antibody-negative 
patient who subsequently seroconverted. Using generalized estimating equation, we identified 
symptoms, signs, and demographic factors predictive of AHI, adjusting for study site. We 
assigned a predictor score to each statistically significant predictor based on its beta coefficient, 
summing predictor scores to calculate a risk score for each participant. We evaluated the 
performance of this algorithm overall and at each site.
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Results—We compared 122 AHI visits with 45 961 visits by uninfected patients. Younger age 
(18–29 years), fever, fatigue, body pains, diarrhoea, sore throat, and genital ulcer disease were 
independent predictors of AHI. The overall area under the receiver operating characteristics curve 
(AUC) for the algorithm was 0.78, with site-specific AUCs ranging from 0.61 to 0.89. A risk score 
of at least 2 would indicate AHI testing for 5–50% of participants, substantially decreasing the 
number needing testing.
Conclusion—Our targeted risk score algorithm based on seven characteristics reduced the 
number of patients needing AHI testing and had good performance overall. We recommend this 
risk score algorithm for use by HIV programs in sub-Saharan Africa with capacity to test high-risk 
patients for AHI.
Introduction
During the first few weeks following HIV-1 acquisition, many people develop an acute 
retroviral syndrome (ARS), a set of nonspecific symptoms and signs, including fever, body 
pains, fatigue, or diarrhoea, for which urgent healthcare is frequently sought [1,2]. These 
symptoms on their own do not confirm acute HIV-1 infection (AHI) [3], but may help 
decide which patients need diagnostic evaluation for AHI [4–7]. Because patients with AHI 
would benefit from counselling and treatment to reduce onward transmission, approaches 
for targeted AHI screening are urgently needed.
AHI is the 2–4 week period before the development of detectable antibodies, when either 
p24 antigen or HIV-1 RNA testing is needed for diagnosis [2,8,9]. Infectiousness is sharply 
elevated during this period, making detection a priority for public health programming. 
Prompt diagnosis of AHI permits counselling for sexual risk reduction and the initiation of 
discussions about antiretroviral therapy (ART). ART has significant benefit for the reduction 
of transmission risk [10], and has recently been demonstrated to reduce morbidity and 
mortality in asymptomatic patients with CD4+ cell counts greater than 500 cells/µl [11,12].
Until recently, prospective screening of at-risk adults for AHI has been challenged by the 
absence of low-cost, rapid point-of-care (POC) p24 antigen or RNA assays in most clinical 
settings in resource-limited countries. In a year of low malaria transmission in coastal Kenya 
(2013), we diagnosed AHI through p24 antigen screening in 1.7% of febrile young adult 
patients seeking outpatient care and reported that AHI was as common as malaria in this 
population [13,14]. Given that POC diagnostics designed for AHI detection are emerging 
and may represent an opportunity for real-time AHI diagnosis in the near future [15], it is 
important to provide guidance on who should be targeted for AHI evaluation in resource-
limited settings where universal screening is not feasible.
In high-prevalence countries such as Kenya and Malawi, two rapid tests are usually used in 
series or parallel to screen for HIV-1 antibodies. Among adults at high risk for HIV-1 
acquisition who had discordant results on parallel rapid tests (i.e., one test positive, other test 
negative) the risk of subsequent HIV seroconversion was four- to 30-fold higher when 
compared with individuals from the same risk groups who tested HIV-1 negative on both 
antibody tests [5,7]. The World Health Organization recommends that patients with 
discordant rapid test results repeat HIV-1 testing 2 weeks later [16]. Ideally, such patients 
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would undergo Nucleic Acid Amplification test testing at the time of serodiscordancy to 
expedite their diagnostic work-up and avoid delays in diagnosis.
Currently, no recommendations exist for patients who seek urgent care for fever or other 
ARS symptoms and have negative HIV antibody test results [14], despite three recent 
studies that have demonstrated the importance of AHI amongst febrile HIV-1-seronegative 
adult patients in Uganda, Kenya and Mozambique [14,17,18]. Published work on ARS has 
identified several symptoms and signs that are commonly reported across African sites [4–
7]. However, published risk score algorithms have generally focused on a combination 
outcome including both AHI (defined as having negative HIV-1 antibody tests but positive 
p24 or HIV-1 RNA tests) and recent seroconversion, as patients with AHI were too few in 
any single study. Because guidelines already exist for the diagnosis and management of 
seroconverters [19], a risk score algorithm specifically developed to identify patients with 
AHI in diverse clinical settings could be valuable.
We therefore aimed to identify predictors of AHI using pooled data from four African 
studies and to assess the value of a risk score algorithm based on significant AHI predictors 
for use in targeting AHI screening.
Methods
We pooled data from three cohort studies and one cross-sectional study that evaluated 
demographic factors, symptoms and signs compatible with ARS, and HIV-1 status among 
adult men and women at high risk for HIV-1 infection, in four different African settings. 
The three cohort studies involved female sex workers (FSW) in Mombasa, Kenya; MSM in 
Kilifi, Kenya; and women reporting sex work or multiple partners in the past 3 months in 
Durban, South Africa. The cross-sectional study recruited sexually transmitted diseases 
(STD) clinic patients in Lilongwe, Malawi. STD clinic patients in Malawi who were HIV-1 
RNA positive but had negative or discordant rapid test results were followed for 
seroconversion. Detailed descriptions of the study settings and research methodologies have 
been previously described [4–7].
Review of risk score algorithms to identify acute HIV-1 infection or recent seroconversion 
in Kenya, Malawi, and South Africa
Characteristics of the study populations, laboratory methods used, symptoms and signs 
ascertained, and predictors identified in these published studies are summarized in Table 1. 
Although no single predictor was identified at all four sites, fever and diarrhoea were 
associated with AHI or recent seroconversion in Mombasa, Kilifi and Lilongwe. Having 
discordant rapid HIV test results (evaluated only in Kilifi and Lilongwe) was the strongest 
predictor of the combined outcome across studies, as it was closely linked to seroconversion.
Study procedures
In all four studies, procedures at study visits included a medical history to establish what 
symptoms had occurred since the previous visit (cohort studies), had preceded care seeking 
(cross-sectional study), or were present at the time of evaluation. In addition, a physical 
examination was conducted to confirm the presence or absence of selected signs, and a 
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blood specimen was collected to evaluate patients for HIV-1 infection according to each 
study’s diagnostic algorithm (details in Table 1). Information on medical history and 
physical examination was collected blinded to HIV status.
Selection of predictor variables for pooled analysis with acute HIV-1 infection outcome
For our pooled-data analysis focused on AHI as an outcome, we selected potential predictor 
variables that were collected by all four study sites. These included a total of 12 variables: 
age; sex; seven reported symptoms, including fever, diarrhoea, fatigue, headache, joint or 
muscle pain, sore throat, and rash; and three physical exam signs, including maculopapular 
rash, any lymphadenopathy, and genital ulcer disease (GUD). Each symptom and sign was 
coded in the dataset as present or absent.
Definition of acute HIV-1 infection and documentation of seroconversion
AHI was defined by a positive HIV-1 RNA or p24 antigen test and two negative rapid 
antibody tests or ELISA assays, followed by documented antibody seroconversion. Patients 
with serodiscordant HIV-1 antibody tests at initial evaluation were also followed until 
seroconversion was documented. The estimated date of infection was determined as follows: 
less than 14 days before the collection date when the sample had a positive RNA viral load 
with negative p24 antigen and negative HIV-1 serology; 14 days before a positive p24 
antigen test (with or without a positive RNA virus load) with negative HIV-1 serology; 18 
days before discordant rapid HIV-1 antibody tests (with or without a positive p24 antigen 
test or positive RNA virus load); or the midpoint between a previously negative and 
subsequently positive HIV-1 serologic test (cohort studies), in the absence of a positive 
RNA viral load or p24 antigen test [20].
Site-specific data
Mombasa—During 1993–1998, FSW were followed at monthly visits at the Ganjoni 
Municipal Clinic in Mombasa, Kenya, with 103 women acquiring HIV-1 [6]. For the 
pooled-data analysis, we used updated data from 1993 through 2014, which included data on 
77 AHI cases. The following three predictors of AHI or recent seroconversion in Mombasa 
[6] were not collected at all four sites: too sick to work, inguinal lymphadenopathy, and 
candidiasis.
Kilifi—During 2005–2012, MSM were evaluated at monthly or quarterly visits, and 73 
MSM acquired HIV-1 [7]. For the pooled analysis, we used updated data from 2005 through 
2014, which included 20 AHI cases. The following predictor of AHI or recent 
seroconversion from Kilifi [7] was not collected at all four sites: any symptomatic STD (i.e., 
urethral or rectal discharge, or rectal pain).
Lilongwe—The dataset used to develop the published risk score algorithm was used [5], 
including data from 14 AHI cases. One predictor from the Lilongwe risk score algorithm 
(i.e., more than one sex partner in the past two months) was not collected at all four sites.
Durban—The dataset of monthly visits by high-risk women analysed for the published 
clinical algorithm was used [4], including data from 11 AHI cases. Three predictors from the 
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Durban algorithm (i.e., loss of appetite, weight loss and vaginal discharge) were not 
collected at all four sites.
We created a variable called ‘‘body pains’’ to indicate the presence of joint or muscle pain, 
as a question about joint or muscle pain was asked at each of the four sites. In total, three 
symptoms and four signs identified as predictors of AHI or recent seroconversion at one or 
more sites were not collected by all four sites and therefore could not be included in the 
pooled-data analysis (indicated in Table 1).
Choice of outcome
Although clinical guidance exists for patients who have HIV-1 serodiscordant or 
seropositive results [16], no guidance is available for how to identify and test HIV-1 
antibody-negative patients in high-prevalence settings. In our pooled dataset, we included 
only AHI patient visits and control visits; data from seroconversion visits (at which one or 
both antibody tests was positive) were excluded from analysis. Data for AHI patients were 
censored at the AHI visit.
Data analysis
To identify predictors of AHI in our pooled-data analysis, we calculated unadjusted 
prevalence odds ratios for medical history (i.e., symptoms) and physical examination 
findings (i.e., signs). We compared characteristics reported at AHI visits with those reported 
at all seronegative visits, using generalized estimating equation (GEE) with a logit link and 
exchangeable correlation matrix to adjust for intra-individual correlation. We constructed 
separate models for two specific domains (i.e., symptoms reported in past month and signs 
present on clinical examination), following the approach of Powers et al. [5]. Characteristics 
associated with AHI at P ≤ 0.15 in bivariate analysis were included in these separate, 
multivariable models for each of the two domains (i.e., symptoms and signs) [5]. We then 
constructed a combined model including age group, sex, site, and all variables with P ≤ 0.15 
in each of the domain-specific models. The final pooled-data model retained only predictors 
associated with AHI at P ≤ 0.05 in this combined model.
Predictor scores and score cut points
Similar to Powers et al. [5], each variable other than site in the pooled-data analysis received 
a predictor score equal to its beta coefficient (natural log of the adjusted prevalence odds 
ratio) from the final GEE model, rounded to the nearest integer. A risk score was then 
calculated for each study participant by summing the predictor scores for each predictor 
present at that visit. We then examined receiver operating characteristics curves to determine 
the optimal cut point of the calculated risk score, both overall and at each site. We also 
calculated the area under the curve (AUC) for the predictive ability of the pooled-data risk 
score algorithm to identify a patient visit at which AHI was diagnosed, overall and at each 
site.
Comparison of acute HIV-1 infection visits and recent seroconverter visits
We were interested in whether there were significant differences in symptoms and signs at 
AHI visits (at which patients were antibody-negative but p24 antigen or HIV-1 RNA 
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positive) and recent seroconverter visits (at which patients were positive on one or more 
HIV-1 antibody tests). We reasoned that such differences might be helpful in recognizing 
early symptoms of ARS. We therefore conducted a separate analysis comparing all AHI 
visits in our pooled-data analysis to the seroconverter visits we had excluded. Because 
patients evaluated for ARS several weeks after infection often have poor recall of symptoms 
[21], we restricted recent seroconverter visits to those conducted within 42 days of the 
estimated date of infection.
Results
A total of 122 visits by AHI patients were compared with 45 961 uninfected patient-visits. 
There were differences in all symptoms and signs reported by AHI patients and by control 
participants across study sites (Table 2), except for reported rash and observed 
maculopapular rash. Kilifi MSM AHI patients had the highest report of any symptom (95%) 
and at least 60% reported fever, fatigue, headache, body aches or sore throat. Although 66% 
of Mombasa FSW AHI patients reported one or more symptoms, no single symptom was 
reported by over half of this group. Up to 50% of Lilongwe STD clinic AHI patients (12 
men and 2 women) reported one or more symptoms, whereas only 27% of the high-risk 
women with AHI from Durban reported one or more symptoms.
The unadjusted prevalence odds ratios of age group, site, sex, and each of the seven 
symptoms and three signs are presented in the first column of Table 3. In the domain-
specific model including all symptoms evaluated (column 3, upper box), fever, diarrhoea, 
fatigue, body pains, and sore throat were all associated with AHI at P ≤ 0.15. In the domain-
specific model including all signs evaluated (column 3, lower box), only GUD was 
associated with AHI at P ≤ 0.15. Age 18–29 years, fever, diarrhoea, fatigue, body pains, 
sore throat, and GUD were all significantly associated with AHI (P ≤ 0.05) in the model 
combining demographic factors, symptoms, and signs (column 4), and so were retained in 
the final model. Predictor scores used for each variable in the final, pooled-data model are 
shown in Table 3, column 5. Of note, sex was not significant in the final model, and was 
thus not given points in the risk score algorithm. Site was included as an adjustment variable 
in the model, rather than as a predictor of AHI. Of note, site was not associated with AHI in 
the final adjusted model.
The overall AUC for the algorithm was 0.78, with site-specific AUCs of 0.77, 0.89, 0.83, 
and 0.61 for Mombasa, Kilifi, Lilongwe, and Durban, respectively. With a risk score cut-off 
of 2, two sites would have high sensitivity (90.0% in Kilifi, 92.9% in Lilongwe) and two 
would have moderate to high specificity (84.8% in Mombasa, 74.1% in Kilifi). In Durban, 
where over 70% of women were asymptomatic, a risk score cut-off of one would improve 
sensitivity. In Kilifi, and Malawi, a higher risk score cutoff of three and four, respectively, 
would improve specificity and decrease the proportion of patients needing AHI evaluation, 
at the expense of decreased sensitivity (Fig. 1). With a risk score cut-off of 2, the predictive 
abilities of the pooled-data algorithm when applied to each site’s data are shown in Table 4. 
A risk score of at least 2 using our pooled-data algorithm would indicate AHI testing for 15, 
26, 50, and 5% of risk populations in Mombasa, Kilifi, Lilongwe, and Durban, respectively.
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When we compared the 122 AHI visits with 148 visits by recent seroconverters at the four 
sites, the only significant difference was a higher report of GUD (21.3 vs. 4.7%, P < 0.02) at 
AHI visits compared with recent seroconverter visits (Supplemental Table 1, http://
links.lww.com/QAD/A804). In Mombasa, comparing 77 AHI visits to 85 recent 
seroconverter visits, there was a higher report of fatigue (35.1 vs. 16.5%, P < 0.007) and 
GUD (17.3 vs. 2.4% respectively, P < 0.01). In Kilifi, comparing 20 AHI visits to 39 recent 
seroconverter visits, there was a higher report of sore throat (60.0 vs. 28.2% respectively, P 
< 0.02). For Lilongwe and Durban, where the numbers of AHI and recent seroconverter 
visits were limited, there were no statistically significant differences.
Discussion
We assessed whether signs and symptoms identified in a pooled-data analysis predicted AHI 
in HIV-1 antibody-negative adults at high risk for HIV-1 acquisition in eastern and southern 
Africa. We pooled data from four study sites in Kenya, Malawi, and South Africa that 
ascertained symptoms, signs, and HIV-1 status over extended periods (>20 years in 
Mombasa, Kenya; and >9 years in Kilifi, Kenya). This analysis allowed us to identify 
demographic factors, symptoms, and signs associated with AHI, including age 18–29 years, 
fever, fatigue, body pains, diarrhoea, sore throat, and GUD. A risk score algorithm based on 
predictor coefficients had good performance in Kilifi and Lilongwe, fair performance in 
Mombasa, and weak performance in Durban. A new algorithm targeting AHI screening 
using p24 antigen or HIV-1 RNA tests to HIV-1-antibody-negative persons with a risk score 
of at least 2 could assist providers in African settings in identifying individuals with AHI, 
who are at very high risk for transmitting HIV-1 infection to their sexual partners.
What are the practicalities of this algorithm? It requires clinicians to complete a 7-item score 
card, capturing age and documenting the presence of any of the five reported symptoms or 
GUD on physical exam. Although all patients seeking care should be offered standard HIV 
counselling and testing per current guidelines, patients who test HIV-1 antibody negative 
and have a calculated risk score of at least 2 would undergo laboratory testing to detect AHI. 
This approach would allow efficient detection of AHI via RNA or p24 testing only in the 
subset of patients most likely to have AHI. Previously, we showed that 1% of adult patients 
aged 18–29 years who were targeted for AHI evaluation using a clinical algorithm and 
agreed to be tested had AHI in Coastal Kenya, whereas approximately 25% of patients 
seeking care were eligible for AHI evaluation [14]. Prospective studies to assess the yield of 
AHI patients diagnosed using our pooled-data algorithm to target AHI testing would provide 
useful information about the performance of the algorithm in additional settings.
Reports of symptoms and signs detected at clinical examination differed by study site in this 
analysis. In Durban, where there is a subtype C epidemic, the majority (73%) of higher risk 
women who acquired HIV-1 remained asymptomatic. Interestingly, most women and men 
who acquired HIV-1 in a large study of seroconversion among subtype C-infected 
discordant couples also remained asymptomatic [22]. Why such a high proportion of women 
in Durban reported no symptoms is unclear. Previously, we showed that patients infected 
with HIV-1 subtypes A, C, or D who participated in a multicentre AHI study in five African 
countries had differences in their ARS symptoms (i.e. subtype C or D had fewer ARS 
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symptoms reported than subtype A) [23]. Although it remains to be elucidated if viral 
properties of transmitted HIV-1 subtypes or differences in innate immune response by 
subtype drive the range of symptoms seen in AHI [24], our risk score algorithm performed 
at least moderately well in three of four settings. A simple approach to AHI screening that 
targets symptoms and signs, when present, may be the most realistic strategy for AHI 
detection in all regions of sub-Saharan Africa, given cost constraints.
In order to reduce ongoing HIV-1 transmission, new strategies will be necessary to find at-
risk adults with undiagnosed HIV-1 infection, including patients with AHI, and link them to 
care. Patients with AHI are the most difficult to diagnose, but can be identified using p24 
antigen testing or HIV-1 RNA-based tests such as NAAT [14]. As new POC tests become 
available, research is urgently needed on which AHI detection strategies are most cost-
effective, which may vary by site or programme. Patients diagnosed with AHI should 
undergo risk reduction counselling and counselling about the benefits of ART initiation, 
both for preventing transmission to their sexual partners and children, and in order to 
preserve immune function and prevent HIV-1-related morbidity and mortality. The cost-
effectiveness of AHI detection should be compared with ongoing efforts to identify patients 
with prevalent HIV-1 based on antibody tests done at care seeking (i.e., provider-initiated or 
diagnostic testing and counselling). Unfortunately, providers currently miss testing 
opportunities, and may identify only those patients with the most advanced 
immunosuppression, who are most obviously in need of testing [19]. Outcomes of a 
combined strategy to test for prevalent and AHI should be modelled in terms of patients 
linked to care and secondary transmission prevented. The cost for AHI screening and the 
yield of AHI cases found will likely be determined by locally prevailing illnesses that 
present with similar symptoms (e.g., malaria, arboviral infections), by clinical setting (e.g., 
HIV-uninfected STD clinic patients in Lilongwe had the highest number of symptoms and 
signs), by gender (i.e., women appear to report fewer symptoms than men) [22,25], and by 
HIV-1 incidence in the target population.
Although our study is unique in the large number of AHI patients included in the pooled 
dataset from four study sites in Africa, it has several limitations. First, because we could 
only include variables collected at all four study sites in the pooled-data model, we may 
have missed one or more important predictors of AHI. Nevertheless, this would not have 
affected performance of the current risk score, which was moderate to very good overall and 
at three of the four sites. Second, some study sites had a particular clinical focus (i.e., on 
seroconversion illness or STD screening), and so may have been more thorough in their 
assessments of certain symptoms or signs. Finally, the at-risk populations included may not 
represent all patients who acquire HIV-1 in African settings; nevertheless, key populations 
are critical in any consideration of how to target testing for AHI to those at highest risk for 
HIV-1 acquisition.
Despite these limitations, our study shows that targeted screening of at-risk adults for AHI 
using a simple algorithm based on seven features (age 18–29 years, fever, fatigue, diarrhoea, 
body pains, sore throat, and GUD) would substantially reduce the number of HIV-1-
seronegative patients requiring testing. Validation of the utility of this model at other 
African sites and wider access to POC HIV-1 RNA testing that enables sites to screen for 
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AHI would help ensure that HIV-1 is diagnosed as early as possible, patients are promptly 
counselled and initiate ART, and that opportunities to reduce HIV-1 transmission are not 
missed.
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Proportion of visits at a given risk score at which AHI testing is indicated, and the 
corresponding sensitivity and specificity of the pooled-algorithm.
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Table 1












Study design Cohort Cohort Cross-sectional Cohort
  Risk group female sex workers MSM Sexually transmitted 
diseases clinic patients
High-risk women
  Number of AHI/seroconversion casesa 103 73 21 28
  Number of visits 7735 visits 6531 visits 860 visits 4845 visits
  Follow-up Monthly Monthly or quarterly None Monthly
Laboratory methods used for AHI and 
antibody detection
ELISA + WB Dual rapid Ab and 
p24ag RNA 
confirmation
Dual rapid Ab, WB 
and RNA
Dual Ab and RNA
Significant predictors of AHI or recent seroconversion
Socio-demographic and behavioural 
factors
  Age (18–24 years) X
  Age (18–29 years) X
  >1 sex partnerb in the past 2 months X
Reported symptoms
  Fever X X X
  Vomitingb X
  Diarrhoea X X X
  Fatigue X
  Headache X
  Body aches (arthralgia, myalgia) X X
  Sore throat X
  Weight lossb X
  Rash X X
  Loss of appetite X
  Swollen lymph nodes X
  Too sick to workb X
  Any symptomatic STDb X
Physical exam signs
  Extra-inguinal lymphadenopathy at ≥2 
sitesb
X
  Inguinal lymphadenopathy at ≥2 sitesb X
  Genital ulcer disease (GUD) X X
  Vaginal dischargeb X
  Vaginal candidiasisb X
Discordant rapid test results X X
AHI, acute HIV infection; STD, sexually transmitted disease; WB, Western Blot.
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a
All AHI patients and patients with only one positive antibody test were followed until documented seroconversion (i.e., two positive antibody 
tests).
b
Predictor could not be included in the pooled-data analysis, as it was not collected at all four sites.
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Table 4
Performance of the final pooled-data algorithm with a risk score of at least 2 when applied to site-specific data 










Sensitivity 58.4% 90.0% 92.9% 18.2%
Specificity 84.8% 74.1% 50.5% 95.4%
Positive predictive value 0.9% 1.0% 3.0% 0.9%
Negative predictive value 99.9% 100.0% 99.8% 99.8%
AUC 0.77 0.89 0.83 0.61
AHI testing indicated 15.3% 26.1% 50.2% 4.6%
AHI, acute HIV infection; AUC, area under the curve; STD, sexually transmitted diseases.
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